

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 01D0305030	(X3) Date Survey Completed 04/11/2023
Name of Provider or Supplier Evergreen Medical Center	Street Address, City, State 101 Crestview Ave, Evergreen, AL	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on a review of the CMS (Centers for Medicare and Medicaid Services) CASPER report, API (American Proficiency Institute) proficiency testing evaluations, and an interview, the laboratory failed to successfully participate in Toxicology testing for Theophylline, Tobramycin and Valproic Acid. The laboratory failed two of three consecutive testing events, Event #2, 2022 and Event #1, 2023 (Failure to Participate). These failures result in the laboratory's initial unsuccessful participation. The findings include: Refer to D2118.</p>
D2118	TOXICOLOGY

CFR(s): 493.845(f)

Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a review of the CMS (Centers for Medicare and Medicaid Services) CASPER report, API (American Proficiency Institute) proficiency testing evaluations, and an interview, the laboratory failed to perform satisfactorily in Toxicology testing for Theophylline, Tobramycin and Valproic Acid for two of three consecutive testing events, Event #2, 2022 and Event #1, 2023 (Failure to Participate). The findings include: 1. A review of the CASPER report revealed the laboratory scored the following: Event #2, 2022 Event #1, 2023 Theophylline = 60 % 0 % Tobramycin = 60% 0 % Valproic Acid = 60 % 0 % 2. The technical consultant confirmed in an interview on 3/15/2023 at 3:00 PM, the laboratory failed to submit their results timely for grading for Chemistry (Toxicology), Event #1, 2023. 3. A review of the API proficiency testing evaluations confirmed the above noted failures.